Real-world Outcomes of Multiple Myeloma: Retrospective Analysis of the Czech Registry of Monoclonal Gammopathies
Jazyk angličtina Země Spojené státy americké Médium print-electronic
Typ dokumentu časopisecké články, pozorovací studie, práce podpořená grantem
PubMed
29793653
DOI
10.1016/j.clml.2018.04.003
PII: S2152-2650(17)31844-X
Knihovny.cz E-zdroje
- Klíčová slova
- Czech Republic, MM, RMG, Survival, Treatment patterns,
- MeSH
- analýza přežití MeSH
- bortezomib terapeutické užití MeSH
- doba přežití bez progrese choroby MeSH
- lenalidomid terapeutické užití MeSH
- lidé středního věku MeSH
- lidé MeSH
- mnohočetný myelom mortalita patologie terapie MeSH
- následné studie MeSH
- prospektivní studie MeSH
- protokoly protinádorové kombinované chemoterapie terapeutické užití MeSH
- registrace statistika a číselné údaje MeSH
- retrospektivní studie MeSH
- senioři nad 80 let MeSH
- senioři MeSH
- staging nádorů MeSH
- thalidomid terapeutické užití MeSH
- transplantace kmenových buněk * MeSH
- věkové faktory MeSH
- Check Tag
- lidé středního věku MeSH
- lidé MeSH
- mužské pohlaví MeSH
- senioři nad 80 let MeSH
- senioři MeSH
- ženské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
- pozorovací studie MeSH
- práce podpořená grantem MeSH
- Geografické názvy
- Česká republika epidemiologie MeSH
- Názvy látek
- bortezomib MeSH
- lenalidomid MeSH
- thalidomid MeSH
INTRODUCTION: Real-world data on patient outcomes and treatment patterns in multiple myeloma (MM) are limited. MATERIALS AND METHODS: The present noninterventional, observational, retrospective analysis of prospectively collected Czech patient medical record data from the Registry of Monoclonal Gammopathies estimated real-world outcomes in adults with a diagnosis of symptomatic MM made between May 2007 and June 2014. RESULTS: In total, 2446 patients had initiated first-line treatment. The median overall survival since the diagnosis (primary endpoint) was 50.3 months (95% confidence interval, 46.1-54.5 months) and decreased with each successive treatment line. A similar trend was observed for progression-free survival and the depth of response. In line with European guidelines and clinical practice, bortezomib-, thalidomide-, and lenalidomide-based regimens were most commonly used across all treatment lines (42.3%, 28.9%, and 18.4%, respectively). In the first line, bortezomib and thalidomide were used most often, with lenalidomide the most commonly used agent in the relapse setting (second to fourth lines). Exploratory analyses revealed that younger age (≤ 65 years), lower international staging system stage, and previous stem cell transplantation were associated with significant improvements in overall and progression-free survival, especially in the early treatment lines. CONCLUSION: The present study is the first analysis of Czech data from the Registry of Monoclonal Gammopathies, and it provides important insights into the real-world management of MM for physicians and healthcare providers.
Department of Clinical Hematology Hospital České Budějovice České Budějovice Czech Republic
Department of Hematology and Transfusion Medicine Hospital Pelhřimov Pelhřimov Czech Republic
Department of Hematology General Hospital Liberec Liberec Czech Republic
Citace poskytuje Crossref.org
